

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

APELLIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on June 1, 2020 for Apellis Pharmaceuticals, Inc.

This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement, annual report and voting instructions, go to www.proxydocs.com/APLS. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.



Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our Annual Meeting and need YOUR participation.



If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for our Annual Meeting, please make this request on or before May 18, 2020.



**For a Convenient Way to VIEW Proxy Materials
– and –
VOTE Online go to: www.proxydocs.com/APLS**



Proxy Materials Available to View or Receive: Annual Report and Proxy Statement

Printed materials may be requested by one of the following methods:

 INTERNET www.investorelections.com/APLS
--

 TELEPHONE (866) 648-8133
--

 *E-MAIL paper@investorelections.com

You must use the 12 digit control number located in the shaded gray box below.

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.



Apellis Pharmaceuticals, Inc. Notice of Annual Meeting



Meeting Type:	Annual Meeting
For holders as of:	April 13, 2020
Date:	June 1, 2020
Time:	10:00 A.M. (Eastern Time)
Place:	Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/APLS for more details

The Board of Directors Recommends a Vote FOR each of the director nominees listed in Proposal 1; and FOR Proposals 2 and 3.

- To elect two Class III directors to hold office until the 2023 annual meeting of stockholders.
Nominees:
(1) Gerald Chan
(2) Cedric Francois
- To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.
- To approve an advisory vote on executive compensation.

Note: To conduct any other business properly brought before the Annual Meeting.

Voting at the Annual Meeting: The Annual Meeting will be a "virtual meeting" of stockholders, which will be conducted exclusively via the Internet. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. In order to attend the meeting online and vote your shares electronically during the meeting, you must register in advance at www.proxydocs.com/APLS prior to the deadline of May 28, 2020 at 5:00 p.m., Eastern Time. Further information about how to attend the Annual Meeting online, vote your shares and submit questions is included in the Proxy Statement.